Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index; 134 of the 178 sources its claims cite were checked for support.

IMPlications of IMP2 in RNA Biology and Disease

Open access
Das, Jessica, Busia-Bourdain, Ottavia, Khan, Khizr M., Wolfe, Andrew L. · 2025 · International Journal of Molecular Sciences

Abstract

Insulin-like growth factor 2 mRNA-binding protein 2 (IMP2) is an RNA-binding protein that positively regulates m6A-modified RNAs involved in critical cellular processes such as metabolism, oncogenesis, and immune function. Here, we elucidate facets of IMP2 biology, including several mechanisms of action on RNA, factors that regulate IMP2 expression, its relevant biological target RNAs, its role in normal development and disease, and its potential as a therapeutic target. IMP2 is a multi-level regulator of metabolism, influencing pathways linked to diabetes, obesity, and adipose function. Through genomic amplification and transcriptional overexpression in cancer cells, IMP2 can drive the initiation and progression of multiple cancer types, and high expression is associated with decreased overall survival of patients with cancer. IMP2 influences normal immune function, inflammation, macrophage polarization, and tumor immune evasion. IMP2 has emerged as a promising therapeutic target, particularly for cancers and metabolic diseases.

Overview

CoChat Summary

## TL;DR

This review synthesizes how IMP2/IGF2BP2 acts as an m6A-dependent RNA-binding protein that regulates RNA stability, translation, and sometimes splicing across metabolism, cancer, and immunity. The paper argues that IMP2 is broadly oncogenic and metabolically important, while also highlighting context-specific exceptions such as its tumor-suppressive role in clear cell renal cell carcinoma.

## Key findings

  • IMP2 is described as a multi-level regulator of metabolism and disease: it influences diabetes, obesity, adipose function, wound healing, fatty liver disease, cancer, immune function, inflammation, macrophage polarization, and tumor immune evasion.
  • In cancer, IGF2BP2 is reported as genomically altered in over 2% of all cancers, with cBioPortal-curated rates including 18% ovarian, 14% cervical, 9% lung, 8% uterine, 5% esophageal/gastric, 4% head and neck, 3% prostate, 3% bladder, 2.8% testicular, 2.8% skin, 2.5% breast, 1.5% colon, 1.3% soft tissue, and 0.8% pancreatic cancers.
  • Pan-cancer survival analysis found high IGF2BP2 mRNA associated with worse overall survival in several cancers, including KIRC (HR = 2.1), HNSC (HR = 2.01), SARC (HR = 2.24), PAAD (HR = 3.21), UCEC (HR = 1.94), LUAD (HR = 1.57), LIHC (HR = 1.68), BLCA (HR = 1.54), and KIRP (HR = 2.03); it was associated with better survival in OV (HR = 0.74) and THCA (HR = 0.2).
  • In type 2 diabetes, the review reports GWAS links to rs4402960 and rs1470579, and states that pancreatic β-cell-specific IGF2BP2 deletion in mice impaired insulin secretion and reduced compensatory β-cell proliferation under high-fat diet challenge.

## Methods

  • This is a review article, not an original experimental study; it synthesizes prior work on IMP2 biology across metabolism, cancer, and immunology.
  • The review draws on multiple evidence types cited in the text, including GWAS, pan-cancer database analyses (e.g., GEPIA2, cBioPortal, Kaplan–Meier Plotter), mouse knockout/transgenic models, and cell-based assays such as RIP, RNA pull-down, luciferase reporter assays, RNA stability assays, and xenograft studies.
  • The main analysis is narrative integration of these studies to describe IMP2 mechanisms, regulation, target RNAs, and disease relevance.

## Limitations

  • The paper explicitly states that it has not been determined whether SNPs in the IMP2 region are causative of T2D phenotypes or whether they share haplotype blocks with other causative elements.
  • The review also notes that some reported effects may be context-dependent or partially explained by off-targets, for example where anti-proliferative effects of IMP2 inhibitors were only partially rescued by biallelic IGF2BP2 knockout.
  • Evident from the text: because this is a review, many conclusions are drawn from heterogeneous prior studies across different models and tumor types, so direct comparability is limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms26062415

Cites

154 of 154 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Mechanisms by which IMP2 regulates target genes. Promoting stabilization and translation are the most commonly reported mechanisms of IMP2 action, followed by competition, alternative splicing, and a report of mRNA degradation. The red circle represents methyl-6-A RNA modification, the blue line represents RNA, AAAA represents poly-A tail, the blue circles represent 7-methyl-G cap structure, the blue squares represent exons, green squares represent alternatively spliced exons, the yellow and pink circles with openings represent RNA degrading enzymes, PABP represents poly-A binding protein, the red Xs represent IMP2 presence preventing binding by other RBPs or miRNAs, which would otherwise bind and inhibit the target RNA. Figure created in Adobe Illustrator version 27.9.
Figure 1 Mechanisms by which IMP2 regulates target genes. Promoting stabilization and translation are the most commonly reported mechanisms of IMP2 action, followed by competition, alternative splicing, and a report of mRNA degradation. The red circle represents methyl-6-A RNA modification, the blue line represents RNA, AAAA represents poly-A tail, the blue circles represent 7-methyl-G cap structure, the blue squares represent exons, green squares represent alternatively spliced exons, the yellow and pink circles with openings represent RNA degrading enzymes, PABP represents poly-A binding protein, the red Xs represent IMP2 presence preventing binding by other RBPs or miRNAs, which would otherwise bind and inhibit the target RNA. Figure created in Adobe Illustrator version 27.9.CC BY · PubMed Central
Figure 2 Venn diagram showing the number of overlapping and independent target RNAs regulated by IMP1, IMP2, and IMP3. CLIP-seq and other sequencing data from the POSTAR3 database [10]. Figure created in Python 3.11.0 using the matplotlib_venn library and Adobe Illustrator version 27.9.
Figure 2 Venn diagram showing the number of overlapping and independent target RNAs regulated by IMP1, IMP2, and IMP3. CLIP-seq and other sequencing data from the POSTAR3 database [10]. Figure created in Python 3.11.0 using the matplotlib_venn library and Adobe Illustrator version 27.9.CC BY · PubMed Central
Figure 3 Upstream regulators of IMP2. Blue represents metabolism, pink represents cancer, and purple represents metabolism, cancer, and other indications. Figure created in Adobe Illustrator version 27.9.
Figure 3 Upstream regulators of IMP2. Blue represents metabolism, pink represents cancer, and purple represents metabolism, cancer, and other indications. Figure created in Adobe Illustrator version 27.9.CC BY · PubMed Central
Figure 4 Validated targets of IMP2 and the disease in which the relationship was reported. Solid lines: IMP2 promotes RNA stability; dotted lines: IMP2 promotes translation; dashed lines: IMP2 promotes both RNA stability and translation; tan line: IMP2 regulates alternative splicing; inhibition symbol: IMP2 promotes RNA degradation; green dotted line: IMP2 promotes both translation of the messenger RNA and directly binds the protein product. Light blue: implicated in metabolism; dark blue: metabolism and other functions; dark purple boxes: metabolism, cancer, and other functions; light purple: metabolism and cancer; light pink: cancer; dark pink: cancer and other functions; orange: cancer and immunology; grey: other functions; yellow: implicated in immunology. Figure created in Adobe Illustrator version 27.9.
Figure 4 Validated targets of IMP2 and the disease in which the relationship was reported. Solid lines: IMP2 promotes RNA stability; dotted lines: IMP2 promotes translation; dashed lines: IMP2 promotes both RNA stability and translation; tan line: IMP2 regulates alternative splicing; inhibition symbol: IMP2 promotes RNA degradation; green dotted line: IMP2 promotes both translation of the messenger RNA and directly binds the protein product. Light blue: implicated in metabolism; dark blue: metabolism and other functions; dark purple boxes: metabolism, cancer, and other functions; light purple: metabolism and cancer; light pink: cancer; dark pink: cancer and other functions; orange: cancer and immunology; grey: other functions; yellow: implicated in immunology. Figure created in Adobe Illustrator version 27.9.CC BY · PubMed Central
Figure 5 Genomic and transcriptional changes to IGF2BP2 in cancer. (A) Rate of IGF2BP2 genomic alterations in tumor samples. Data from the cBioPortal curated set of non-redundant studies [77,78,79]. (B) Cancers with decreased expression relative to normal tissue of IGF2BP2 messenger RNA in log2(TPM+1) from tumor (T) relative to normal tissue (N) from the GEPIA2 database [81]. Log fold change between tumor and normal tissue: ACC (−2.66), BRCA (−1.78), and KIRC (−1.95). (C) Cancers with increased expression relative to normal tissue of IGF2BP2 messenger RNA in log2(TPM+1) from tumor (T) relative to normal tissue (N) from the GEPIA2 database [81]. Log fold change between tumor and normal tissue: ESCA (3.74), HNSC (2.85), UCS (2.27), GBM (2.16), PAAD (1.94), OV (1.84), STAD (1.77), READ (1.73), TGCT (1.56), COAD (1.47), SKCM (1.32), LIHC (1.13), LUSC (1.12). See the Abbreviations section for definitions of acronyms. Figure adapted in Adobe Illustrator version 27.9.
Figure 5 Genomic and transcriptional changes to IGF2BP2 in cancer. (A) Rate of IGF2BP2 genomic alterations in tumor samples. Data from the cBioPortal curated set of non-redundant studies [77,78,79]. (B) Cancers with decreased expression relative to normal tissue of IGF2BP2 messenger RNA in log2(TPM+1) from tumor (T) relative to normal tissue (N) from the GEPIA2 database [81]. Log fold change between tumor and normal tissue: ACC (−2.66), BRCA (−1.78), and KIRC (−1.95). (C) Cancers with increased expression relative to normal tissue of IGF2BP2 messenger RNA in log2(TPM+1) from tumor (T) relative to normal tissue (N) from the GEPIA2 database [81]. Log fold change between tumor and normal tissue: ESCA (3.74), HNSC (2.85), UCS (2.27), GBM (2.16), PAAD (1.94), OV (1.84), STAD (1.77), READ (1.73), TGCT (1.56), COAD (1.47), SKCM (1.32), LIHC (1.13), LUSC (1.12). See the Abbreviations section for definitions of acronyms. Figure adapted in Adobe Illustrator version 27.9.CC BY · PubMed Central
Figure 6 Kaplan–Meier analysis of cancers where higher IGF2BP2 expression is significantly associated with decreased (A–I) or increased (J–K) overall survival; data was obtained from Kaplan–Meier Plotter [82,83]. Patients were stratified into high and low IGF2BP2 expression groups based on median expression of IGF2BP2. Only cancers where IGF2BP2 is significantly associated with survival are displayed: KIRC (A), HNCSC (B), SARC (C), PAAD (D), UCEC (E), LUAD (F), LIHC (G), BLCA (H), KIRP (I), THCA (J), and OV (K). Please see the Abbreviations section for definitions of acronyms. Figure adapted in Adobe Illustrator version 27.9.
Figure 6 Kaplan–Meier analysis of cancers where higher IGF2BP2 expression is significantly associated with decreased (A–I) or increased (J–K) overall survival; data was obtained from Kaplan–Meier Plotter [82,83]. Patients were stratified into high and low IGF2BP2 expression groups based on median expression of IGF2BP2. Only cancers where IGF2BP2 is significantly associated with survival are displayed: KIRC (A), HNCSC (B), SARC (C), PAAD (D), UCEC (E), LUAD (F), LIHC (G), BLCA (H), KIRP (I), THCA (J), and OV (K). Please see the Abbreviations section for definitions of acronyms. Figure adapted in Adobe Illustrator version 27.9.CC BY · PubMed Central

Verification

Claims the paper makes

105 Valid · 13 Not valid · 28 Not checked · 9 Own results and interpretations

67 more claims · 47 with their cited sources checked

Create a free account to see all 155 claims and to verify the 19 references still open.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 75

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 154 references

Cited by

See all 3

Metadata

Authors
Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L.
Affiliations
  • The Graduate Center, CUNY (US)
  • City University of New York (US)
Corresponding author
Wolfe, Andrew L.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2025-03-07
Volume
26
Issue
6
Pages
2415
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4408226515
Cited by
3
References
154
Citations by year
2026: 3
FWCI
0.26
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (U54CA221704, R00CA226363, 2318923, ENHC55171)
  • Hunter College of the City University of New York (U54CA221704, R00CA226363, 2318923, ENHC55171)
  • National Science Foundation (U54CA221704, R00CA226363, 2318923, ENHC55171)
  • PSC-CUNY Research (U54CA221704, R00CA226363, 2318923, ENHC55171)
  • Oncogenuity, Inc. (U54CA221704, R00CA226363, 2318923, ENHC55171)
  • DASNY GRTI (U54CA221704, R00CA226363, 2318923, ENHC55171)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
Keywords
IGF2BP2, RNA-binding proteins, m6A RNA methylation, RNA metabolism, cancer, metabolic disorders, diabetes mellitus, obesity, adipose tissue, gene amplification, carcinogenesis, tumor immune evasion, macrophage polarization, inflammation, therapeutic target
MeSH terms
Animals, Humans, Neoplasms, RNA, RNA-Binding Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IMPlications of IMP2 in RNA Biology and Disease. https://app.cochat.ai/papers/10.3390/ijms26062415
The paper
Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L. (2025). IMPlications of IMP2 in RNA Biology and Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062415

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.